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Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare genetic
disorder belonging to the group of vacuolating leukodystrophies. It is characterized
by megalencephaly, loss of motor functions, epilepsy, and mild mental decline. In
brain biopsies of MLC patients, vacuoles were observed in myelin and in astrocytes
surrounding blood vessels. It is mainly caused by recessive mutations in MLC1 and
HEPACAM (also called GLIALCAM) genes. These disease variants are called MLC1 and
MLC2A with both types of patients sharing the same clinical phenotype. Besides,
dominant mutations in HEPACAM were also identified in a subtype of MLC patients
(MLC2B) with a remitting phenotype. MLC1 and GlialCAM proteins form a complex
mainly expressed in brain astrocytes at the gliovascular interface and in Bergmann glia at
the cerebellum. Both proteins regulate several ion channels and transporters involved in
the control of ion and water fluxes in glial cells, either directly influencing their location and
function, or indirectly regulating associated signal transduction pathways. However, the
MLC1/GLIALCAM complex function and the related pathological mechanisms leading to
MLC are still unknown. It has been hypothesized that, in MLC, the role of glial cells in
brain ion homeostasis is altered in both physiological and inflammatory conditions. There
is no therapy for MLC patients, only supportive treatment. As MLC2B patients show an
MLC reversible phenotype, we speculated that the phenotype of MLC1 and MLC2A
patients could also be mitigated by the re-introduction of the correct gene even at later
stages. To prove this hypothesis, we injected in the cerebellar subarachnoid space of
Mlc1 knockout mice an adeno-associated virus (AAV) coding for human MLC1 under the
control of the glial-fibrillary acidic protein promoter. MLC1 expression in the cerebellum
extremely reduced myelin vacuolation at all ages in a dose-dependent manner. This study
could be considered as the first preclinical approach for MLC. We also suggest other
potential therapeutic strategies in this review.
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INTRODUCTION
Leukodystrophies are human diseases affecting the central
nervous system (CNS) myelin. Although individual
leukodystrophies are rare, epidemiological data are
indicating their high incidence. Within the leukodystrophies,
Megalencephalic leukoencephalopathy with subcortical cysts
(MLC; MIM 604004) is a vacuolating white matter disorder
of infantile-onset (van der Knaap et al., 2012). Macrocephaly
is observed in all affected individuals and develops during the
first year of life. Most patients show delayed mental or motor
development and seizures (Hamilton et al., 2018). Magnetic
resonance imaging (MRI) is crucial to diagnose the disease in
childhood, showing diffuse signal abnormality, swelling of the
cerebral white matter, and the presence of subcortical cysts,
which are mostly present in the anterior temporal areas and
often in the frontoparietal region (van der Knaap et al., 1995).
From this initial presentation, which is common to all
MLC patients, two different phenotypes have been described:
a classical phenotype, which is found in the majority of
patients, and an improving phenotype, which shows a bettering
clinical course (van der Knaap et al., 2010). In the MLC
classical phenotype, there is a gradual onset of ataxia, spasticity,
and sometimes extrapyramidal findings; and late-onset of
mild mental deterioration. In the improving phenotype,
motor function ameliorates or normalizes; some patients
have stable intellectual disability, with or without autism
(Hamilton et al., 2018).
The classical MLC can be caused by two biallelic mutations
in the MLC1 or HEPACAM genes, as the disease is inherited
in a recessive manner (Leegwater et al., 2001; López-Hernández
et al., 2011a). Classical MLC patients with mutations in MLC1
are diagnosed as MLC1 type, whereas those with mutations
in HEPACAM are named MLC2A. The improving phenotype,
on the other hand, is caused by heterozygous mutations in
HEPACAM (López-Hernández et al., 2011a). These patients
are diagnosed as MLC2B type, and the disease is inherited
dominantly. Mutations in MLC1 and HEPACAM are found in
76% and 22% of the patients, respectively. Pathogenic variants in
MLC1 or HEPACAM have not been identified in the remaining
2% of individuals showing clinical features of MLC, suggesting
the existence of unknown additional genes of the disease
(van der Knaap et al., 1993).
MLC1 encodes for an integral oligomeric membrane protein
of unknown function expressed only in astrocytes, being one
of the most specific proteins for this cellular type (Teijido
et al., 2004, 2007; Boor et al., 2005; Ambrosini et al., 2008).
Mutations found in MLC1 patients are distributed all over
the protein and they cause protein instability, which leads
to its degradation at the endoplasmic reticulum (ER) or in
lysosomes (Duarri et al., 2008; Lanciotti et al., 2010; Petrini
et al., 2013). HEPACAM encodes for a single transmembrane
type I protein (Moh et al., 2005), which works as an adhesion
molecule called HepaCAM or GlialCAM, the latter reflecting
its higher expression in glial cells (Barrallo-Gimeno et al.,
2015). GlialCAM can form homophilic interactions with other
GlialCAM molecules within the same cell (cis interactions) and
between different cells (trans interactions; Elorza-Vidal et al.,
2020). Most missense mutations found in MLC2A or MLC2B
patients are located in the extracellular domain of the protein,
and affect protein localization at cell-cell junctions (López-
Hernández et al., 2011a; Arnedo et al., 2014a,b; Elorza-Vidal
et al., 2020). A recessive mutation in the signaling peptide of
GlialCAM (p.L23H) abolishes protein expression in transfected
cells in vitro, suggesting that the lack of GlialCAM expression
can also cause the disease (Arnedo et al., 2014b). Based on recent
biochemical and structural data, it seems that missense dominant
MLC2B mutations specifically affect GlialCAM cis and trans
interaction surfaces (Elorza-Vidal et al., 2020).
GlialCAM exerts two roles on MLC1: on one hand, it
acts as an ER chaperone (Capdevila-Nortes et al., 2013) and,
on the other hand, it confines MLC1 at astrocyte-astrocyte
junctions (López-Hernández et al., 2011b). Thus, most MLC2A
and MLC2B HEPACAM mutations affect GlialCAM targeting
and, consequently, also MLC1 location to cell-cell junctions. As
GlialCAM improves MLC1 folding, co-expression of GlialCAM
with mutated MLC1 increases levels of MLC1 protein and its
membrane expression (Capdevila-Nortes et al., 2013).
EFFECT OF MLC MUTATIONS INTO
GLIALCAM AND MLC1 CELL BIOLOGY
Different cellular models have been used to express wild-type
MLC1 and GlialCAM or containing MLC mutations, such as
Xenopus oocytes (Teijido et al., 2004), Spodoptera frugiperda
(Sf9) cells (Ridder et al., 2011) and other cell lines such
as fibroblast HeLa (López-Hernández et al., 2011b), COS-1
(Hwang et al., 2019), HEK293 or glioblastoma U373 (Ambrosini
et al., 2008) and human U251 astrocytoma (Lanciotti et al.,
2020). Other studies have been performed in primary astrocyte
cultures from mice, rats, and humans (Duarri et al., 2011;
Ridder et al., 2011; Brignone et al., 2014). Finally, studies
have also been performed in lymphoblast cell lines and
human monocytes or monocyte-derived macrophages from
control and MLC patients (Duarri et al., 2008; Petrini et al.,
2013). Studies with human astrocytes derived from iPS
cells would also be useful to gather more information on
the disease.
From a pathological point of view, these studies in cell lines
have defined the biochemical mechanism of how different MLC
mutations affect different parameters such as protein stability,
protein levels at the plasma membrane, and protein localization.
Thus, it is clear that most MLC1 missense mutations cause
protein degradation. This has been verified in Xenopus oocytes
(Duarri et al., 2008), different cell lines (Duarri et al., 2008;
Brignone et al., 2014), primary astrocyte cultures (Duarri et al.,
2008), monocytes from patients (Duarri et al., 2008; Petrini
et al., 2013), and even in a brain biopsy of an MLC1 patient
(López-Hernández et al., 2011b; Figure 1A). Therefore, cells or
animals deficient in MLC1 constitute a model to understand
the pathophysiology of MLC. Animal models containing a
missense mutation inMLC1 could be used to screen for chemical
chaperones that could increase MLC1 protein stability and
consequently, its levels at the plasma membrane.
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FIGURE 1 | Effect of MLC1 (A) and GLIALCAM (B) mutations on the
biochemistry and cell biology of their coding proteins. (A) Top panel:
2D-scheme of the MLC1 protein showing the residues that are mutated in
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) patients.
Below panel: mutation S69L found in a Spanish MLC1 patient abolished
MLC1 protein expression. Reprinted by permission from Oxford University
Press: Human Molecular Genetics, Molecular mechanisms of MLC1 and
GLIALCAM mutations in MLC, López-Hernández et al. (2011b). (B) 3D-Model
of GlialCAM homo-oligomers forming cis and trans interactions. Reprinted by
permission from Oxford University Press: Human Molecular Genetics,
Structural basis for the dominant or recessive character of GLIALCAM
mutations found in leukodystrophies, Elorza-Vidal et al. (2020). Expression of
GlialCAM containing a recessive (R92Q) or a dominant (R92W) mutation in
primary astrocytes causes mistargeting.
On the other hand, most mutations in HEPACAM cause
protein mislocalization, as shown in cell lines and cultured
astrocytes (Figure 1B). Biochemical studies also suggest that
dominant MLC2B mutations affect the trafficking of the
wild-type protein, possibly by interfering with the formation
of GlialCAM complexes in the same cell (cis-interactions) or
between different cells (trans-interactions; Elorza-Vidal et al.,
2020). These in vitro studies were validated in vivo with the
generation of a Glialcam knockin (KI) mouse containing a
dominant mutation, which showed that GlialCAM protein also
displays a trafficking defect in heterozygous mice (Hoegg-Beiler
et al., 2014). With this model, it has been speculated that
dominant MLC2B mutations may lead to a minor reduction
of GlialCAM/MLC1 function, which might be pathogenic
in humans only at the early stages of life. In agreement
with the reversibility of the phenotype observed in MLC2B
patients in adult stages, a decreased GlialCAM/MLC1 function
may not be so pathogenic in adults as it is in infants
(Hamilton et al., 2018).
Very few HEPACAM mutations seem to induce a
gain of function, a phenotype that can only be observed
in astrocytes from Mlc1 knockout mice in depolarizing
conditions (Arnedo et al., 2014b). Further work is needed





It has nearly been 20 years since the discovery of the first
gene implicated with the disease, MLC1 (Leegwater et al., 2001).
However, we still do not have a clear picture of the function
this protein exerts, and hence, the pathophysiology of the disease
remains obscure (Estévez et al., 2018).
First insights into the putative role of MLC1 came from
protein sequence analysis (Leegwater et al., 2001). Thus, it
was suggested that MLC1 could work as an ion channel or
a transporter. However, no ion or transport activity directly
mediated by MLC1 has been demonstrated so far, even when
co-expressed with GlialCAM (Teijido et al., 2004). Based on the
clinical phenotype of the patients, it was then speculated that
water/ion homeostasis should be negatively affected by the lack
of MLC1 (van der Knaap et al., 2012).
To get more insights into the role of GlialCAM/MLC1,
several research groups aimed to identify first the MLC1 and
later GlialCAM interacting proteins. Different approaches were
addressed such as yeast-to-hybrid, using MLC1 N-terminal
domain (Brignone et al., 2011) or the full-length MLC1
(unpublished results from our group), immunopurification of
MLC1 or GlialCAM associated complexes (López-Hernández
et al., 2011a; Jeworutzki et al., 2012; Sugio et al., 2017),
co-fractionation (sWGA and DEAE chromatography, ouabain
chromatography; Ambrosini et al., 2008; Brignone et al., 2011,
2014), co-localization (by confocal or electronic microscopy
immunogold) and by testing possible candidates (Lanciotti et al.,
2012). All these studies resulted in a list of proteins that might be
involved in MLC (Table 1).
Classically, two approaches were followed to understand
the role played by MLC and MLC-interacting proteins. One
method compared the effects of overexpressing wild-type MLC1
(with or without GlialCAM) with the effects of overexpressing
MLC1-containing mutations. However, an important caveat has
to be stated in this method. Overexpression of Mlc1 is very toxic
in mice (Sugio et al., 2017), leading to a more drastic vacuolation
phenotype than in theMlc1 knockout mice. Also, overexpression
of a protein folding mutant may cause alterations in the ER and
in lysosomes leading to additional effects (Duarri et al., 2008).
On the other hand, other groups explored the effects of partially
or totally depleting MLC proteins. Also, some studies have
functionally analyzed the activity of possible interacting proteins
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TABLE 1 | Proteins that have been related to the Megalencephalic leukoencephalopathy with subcortical cysts (MLC) proteins.
Protein related
with MLC
Genetical, cell biology and
biochemical evidence
Overexpression Reduction of expression Some comments
GlialCAM 1. Mutations in GLIALCAM
cause MLC (López-Hernández
et al., 2011a).
2. GlialCAM interact with MLC1
in vitro: co-IP, FRET, split-TEV
(López-Hernández et al.,
2011b).
3. Co-localization and co-IP







stabilize MLC1 wild-type and
mutants (Capdevila-Nortes et al.,
2013).
1. KO of Glialcam affect
MLC1 expression and localization
(Hoegg-Beiler et al., 2014; Bugiani
et al., 2017).
2. KO of Mlc1 affect GlialCAM
localization (Hoegg-Beiler et al.,
2014; Bugiani et al., 2017).
There is no doubt that GlialCAM is a
obligate subunit of MLC1 in vivo.
However, MLC1 overexpressed
in vitro arrive at the PM
independently of GlialCAM.
ClC-2 1. ClC-2 interact with GlialCAM
and MLC1 in vitro: coIP,
split-TEV, stabilization at the PM
(Jeworutzki et al., 2012;
Gaitán-Peñas et al., 2017).
2. Co-localization and co-IP
in vivo (Jeworutzki et al., 2012).
3. ClC-2 localization change by
GlialCAM (Jeworutzki et al.,
2012).
Overexpression of ClC-2 and
GlialCAM change functional
properties of ClC-2 (Jeworutzki
et al., 2012, 2014).
1. KO of Mlc1 and Glialcam change
ClC-2 localization and functional
properties (Hoegg-Beiler et al.,
2014; Bugiani et al., 2017).
2. In KO of ClC-2 there is a slight
increase of MLC1 (Hoegg-Beiler
et al., 2014).
The association between
GlialCAM/MLC1 and ClC-2 is not
constitutive (Sirisi et al., 2017).
ClC-2 KO and/or mutations of
CLCN2 have a different phenotype
than MLC (Depienne et al., 2013).
ClC-2 dysfunction might contribute
to MLC but it is not the whole story
(Hoegg-Beiler et al., 2014).
Na+/K+-ATPase 1. β1 subunit interact with
MLC1 N terminus by Yeast
two-hybrid and pull down
in vitro (Brignone et al., 2011).
However, β1 was not co-IP
in vivo (Sugio et al., 2017).
2. α2 and α3 subunits were
co-IP in vivo (Sugio et al.,
2017).
3. Some colocalization in
astrocytes (Brignone et al.,
2011).
4. Ouabain chromatography
purified MLC1 (Brignone et al.,
2011).
5. Other proteins copurifying
with Na+/K+-ATPase also are
found in MLC1 IP (i.e., GLAST,
GLT-1; Sugio et al., 2017).
Astrocytes from mice with
MLC1 OE show reduced
Na+/K+-ATPase activity, but
increased ouabain binding (Sugio
et al., 2017).
1. No change in activity were
observed in Mlc1 KO mice (Sugio
et al., 2017).
2. No change in localization were
observed in MLC KO mice (Dubey
et al., 2015; Bugiani et al., 2017).
In vitro studies expressing these
proteins are needed to prove their
interaction. More evidence in vivo
that Na+/K+-ATPase activity is





1. They have been identified by
coIP from brain tissue or by
pulldown from astrocytes
expressing His-tagged MLC1
(Brignone et al., 2014; Sugio
et al., 2017).
2. Some co-localization have
been demonstrated by IF in
astrocytes with V-ATPase
(Brignone et al., 2014).
In the case of V-ATPase: OE of
MLC1 influences endosomal pH
(Brignone et al., 2014).
No studies have been
performed in KO animals.
In vitro studies expressing these
proteins are needed to prove their
interaction. More evidence in vivo




1. No coIP in vivo (Elorza-Vidal
et al., 2018).
2. No colocalization in tissue
and in primary astrocytes
(Elorza-Vidal et al., 2018).
OE MLC1 but not GlialCAM
increases VRAC activity and
improves RVD (regulatory volume
decrease; Ridder et al., 2011;
Lanciotti et al., 2012;
Capdevila-Nortes et al., 2013).
1. Mlc1 KO or Mlc1/Glialcam
depletion reduces VRAC activity
and RVD in astrocytes
(Capdevila-Nortes et al., 2013;
Dubey et al., 2015; Elorza-Vidal
et al., 2018).
It is not clear how VRAC activity is
regulated by MLC1. It may be an
indirect or a compensatory
mechanism. More experimental
evidence is needed. For instance,
VRAC current should be measured
in brain slices from MLC KO
models.
(Continued)
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TABLE 1 | Continued
Protein related
with MLC
Genetical, cell biology and
biochemical evidence
Overexpression Reduction of expression Some comments
2. Lymphoblast MLC cell lines
show reduced VRAC activity
(although MLC1 mRNA
expression is nearly negligible in
WT cells; Ridder et al., 2011).
Cx43 1. coIP in vivo with GlialCAM
(our unpublished results) and
in vitro in U373G cells (Wu
et al., 2016).
2. Partial co-localization with
MLC1 and GlialCAM in primary
astrocytes (Duarri et al., 2011).
1. OE MLC1 in U251 cell line
reduces ERK1/2 activity which
phosphorylates
Cx43 increasing Cx43 in gap
junctions (Lanciotti et al., 2020).
2. OE GlialCAM in U373G cell
line increase Cx43 stability (Wu
et al., 2016).
1. No experiments have been
performed in KO animals.
2. Cx43 is misslocalized in
Glialcam KO astrocytes (our
unpublished results).
Experiments in vivo in KO MLC
models are needed. It seems
that MLC1 may influence
different proteins indirectly by
influencing signaling through
ERK1/2 (VRAC, Cx43; Lanciotti
et al., 2016).
TRPV4 1. It has been identified by





purified also TRPV4 (Lanciotti
et al., 2012).
1. Astrocytes OE MLC1 activate
calcium influx in response to
hyposmosis and 4αPDD more
efficiently (Lanciotti et al., 2012).
2. MLC1 also favors recycling of
TRPV4 (Lanciotti et al., 2012).
1. No experiments have been
performed in KO animals or
astrocytes.
2. In macrophages from
patients Ca2+ responses are
also affected (Petrini et al.,
2013).
It is not clear how
TRPV4 activity is regulated by
MLC1. It may be an indirect or
a compensatory mechanism.
More experimental evidence is
needed.
Kir4.1, AQP4 1. They have been identified by
co-fractionation, ouabain
chromatography or pulldown,
mainly in cell culture
(Brignone et al., 2011).
2. AQP4 association seem to
increase in hypoosmotic
conditions
(Lanciotti et al., 2012).
3. In vivo there is no
colocalization by EM with these
proteins in tissue
(Duarri et al., 2011).
In vitro experiments in Xenopus
oocytes show that MLC1 does
not influence Kir4.1 channel
activity (Teijido et al., 2004).
In KO animals or in brain MLC
biposies there is a redistribution
of AQP4 and Kir4.1, which has
been interpreted as a
compensatory mechanism
(Dubey et al., 2015; Wu et al.,
2016; Bugiani et al., 2017).
In vitro studies expressing these
proteins are needed to prove
their interaction. More evidence
in vivo that their activity is





1. They include: syntrophin,
dystrophin, caveolin-1, ZO-1.
2. ZO-1 has been identified by
coIP from brain. Co-localization
has been found by EM in tissue
and IF in primary astrocytes
(Duarri et al., 2011).
3. GlialCAM, MLC1 and other
related proteins (i.e., TRPV4)
are found in caveolae (Lanciotti
et al., 2010).
4. Syntrophin and Dystrophin
are found by co-fractionation
and pulldown (Ambrosini et al.,
2008). There is no
colocalization with MLC1 by EM
(Duarri et al., 2011). KO of
Dystrophin, α-Dystrobrevin and
Utrophin does not affect
MLC1 localization (Duarri et al.,
2011).
No studies have been
performed in OE mice or in
transfected cells.
No changes in localization have
been reported in Mlc1 or
Glialcam KO animals (Dubey
et al., 2015; Bugiani et al.,
2017).
1. Some of these proteins may
help anchor MLC1 and
GlialCAM at specific locations,
so it is logical that its
localization is not affected in KO
animals.
2. In vivo, it is not clear that
MLC1 forms part of the DGC
complex, since there is no
colocalization between proteins
of the DGC complex and MLC
proteins.
We indicate the biochemical evidence, the functional effects after overexpression or inhibition, and a conclusion of the effects.
in animal models of the disease (knockouts or overexpression)
and/or cells obtained from patients.
In general, we can conclude that many different transporters
or ion channels seem to be affected in MLC. Some of the proteins
affected might be directly interacting with GlialCAM/MLC1
(i.e ClC-2, Cx43, Na+/K+-ATPase), whereas others might
be regulated in an indirect manner (i.e., VRAC, TRPV4).
An interesting new hypothesis is that GlialCAM/MLC1 may
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modulate signal transduction events, and therefore, they
could simultaneously influence different proteins (Lanciotti
et al., 2016; Elorza-Vidal et al., 2018; Brignone et al., 2019).
However, it is difficult to conclude whether the functional
changes observed in these proteins are a consequence of a
compensatory mechanism or a direct effect of MLC proteins.
Possibly, those effects that show a different sign of change in
overexpressing vs. reduced expression and that directly interact
with GlialCAM/MLC proteins are probably a direct consequence
of GlialCAM/MLC1 functional role. We indicate the results
obtained for different proteins in Table 1.
An interesting issue is that some interactions might be
constitutive, such as those between GlialCAM and MLC1
(Sirisi et al., 2014), whereas others might be regulated,
such as the interaction between GlialCAM/MLC1 and
ClC-2 (Sirisi et al., 2017). Hence, GlialCAM/MLC1 could
be forming a protein scaffold, where different proteins
may interact in a regulated manner with this protein
network resulting in activity changes. As the interaction
with ClC-2 was dependent on extracellular potassium,
we proposed that GlialCAM/MLC1 might regulate brain
homeostasis by influencing the activity and the interaction
with different transporters/ion channels that could be
involved in controlling brain potassium levels (Estévez et al.,
2018). Apart from myelin vacuoles, defects in potassium
clearance and increased excitability were described in MLC
knockout mice and MLC patients (Dubey et al., 2018;
Hamilton et al., 2018).
ANIMAL MODELS OF MLC: ZEBRAFISH
AND MICE
To understand the pathophysiology of MLC, several animal
models have been generated. In mice, three different knockout
lines of Mlc1 were produced (Hoegg-Beiler et al., 2014; Dubey
et al., 2015; Sugio et al., 2017), two different knockouts for
Glialcam (Hoegg-Beiler et al., 2014; Bugiani et al., 2017),
several KI mice for Glialcam containing dominant or recessive
mutations affecting GlialCAM targeting (Hoegg-Beiler et al.,
2014; Shi et al., 2019), double KO forMlc1 and Glialcam (Pérez-
Rius et al., 2019), and a transgenic mouse that overexpress Mlc1
in astrocytes (Sugio et al., 2017). It will be interesting to use
Mlc1 floxed mice to generate conditional KO specifically in
astrocytes during development, or KI mice for Mlc1 containing
missense mutations as well as to obtain tissue-specific knockouts
for GlialCAM. In zebrafish, an mlc1 KO line has been
generated (Sirisi et al., 2014), with a mutation that abolishes
mlc1 expression in vitro and in vivo; a glialcamaKO and a double
KO formlc1 and glialcama (Pérez-Rius et al., 2019).
All knockout animals share with human MLC patients an
increase in the brain water content (Figure 2), which can be
easily detected by MRI or histological techniques. As in biopsies
of MLC patients (van der Knaap et al., 1996), vacuoles observed
in animal models using electron microscopy are intramyelinic
(Figure 2). However, some differences exist between human and
animal models. MRI defects are observed in humans during the
first years of life, thus there is a correlation between the period
FIGURE 2 | The vacuolating phenotype of GlialCAM and MLC1 in mice and
zebrafish resembles the MLC phenotype observed in humans. (A–C) MRI
images of a human MLC1 patient (A), Mlc1 knockout mice (B), and mlc1
knockout zebrafish (C). Red arrows indicate areas with increased water.
Reprinted by permission from Oxford University Press: Human Molecular
Genetics, Molecular mechanisms of MLC1 and GLIALCAM mutations in
megalencephalic leukoencephalopathy with subcortical cysts,
López-Hernández et al. (2011b) and by permission from Oxford University
Press: Human Molecular Genetics, Megalencephalic leukoencephalopathy
with subcortical cysts protein 1 regulates glial surface localization of
GLIALCAM from fish to humans, Sirisi et al. (2014). (D) Histology studies of
cerebellar brain white matter comparing wild-type (left) with Mlc1 KO mice
indicate the presence of vacuoles in the KO mice. (E) EM images of vacuoles
in Mlc1 KO mice.
where myelination is more active and the onset of vacuolization.
However, it takes much more time to be seen in mice (Hoegg-
Beiler et al., 2014; Dubey et al., 2015), and even longer in zebrafish
(Sirisi et al., 2014). In line with these differences, expression
of MLC1 and GlialCAM is also higher in humans in the first
years of life and then is reduced and maintained (Dubey et al.,
2015; Bugiani et al., 2017), whereas expression of both proteins
increases slowly in mice, reaching its peak at adult stage (Teijido
et al., 2007; Gilbert et al., 2019).
Furthermore, there are also regional differences in vacuolated
areas. It is important to mention that in humans the edema
is mostly found in the subcortical white matter. While mice
have a much more limited subcortical white matter, vacuoles are
found in the cerebellum of KO mice, although MLC1 is broadly
expressed at the endfeet of astrocytes in the whole brain (Hoegg-
Beiler et al., 2014). Thus, it can be speculated that MLC1 and
GlialCAM physiological roles might be more important in the
cerebellum than in the rest of the brain or that they might play
additional roles in cerebellar Bergmann glia. Several observations
support these hypotheses: (1) inmice, expression of both proteins
in the cerebellum is higher than in the rest of the brain (Teijido
et al., 2007; López-Hernández et al., 2011a); (2) knockout ofMlc1
reduces total expression of Glialcam and ClC-2 in the cerebellum,
whereas no changes are observed in the cerebrum (Hoegg-Beiler
et al., 2014). Similarly, knockout ofGlialcam decreases expression
of ClC-2 in the cerebellum, but not in the rest of the brain. These
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results are in agreement with the formation of a ternary complex
between GlialCAM, MLC1, and ClC-2 that stabilizes ClC-2 in
the cerebellum (Sirisi et al., 2017); (3) in a brain biopsy of an
MLC1 patient, lack of MLC1 causes GlialCAM mislocalization
in Bergmann glia (Sirisi et al., 2014), but not in the rest of the
brain (López-Hernández et al., 2011b); and (4) overexpression
of Mlc1 causes a reduction in cerebellar size and Bergmann
glia ectopia by an unknown mechanism in a development-
dependent manner (Kikuchihara et al., 2018). Thus, we postulate
that GlialCAM/MLC1 may have more importance or additional
roles in the cerebellum, and this is perhapsmore relevant inmice.
Different from MLC patients, the MLC mouse model
containing a deletion of the first two exons of Mlc1 (Hoegg-
Beiler et al., 2014) does not display any cognitive or motor
deficits and it is considered a model for the early stages of
the disease. In contrast, the Mlc1 KO where the full Mlc1 gene
was replaced by GFP showed some motor defects and higher
susceptibility to develop epileptic seizures after kainate insults
(Dubey et al., 2018). It remains to be determined whether these
differences are due to the different targeting strategies and/or to
genetic background.
One interesting result observed in animal models is the
mutual dependence between GlialCAM and MLC1. Thus,
in mice and zebrafish, lack of Mlc1 causes GlialCAM
mislocalization but not the reduced expression (Hoegg-
Beiler et al., 2014; Sirisi et al., 2014) and, in mice, lack of
GlialCAM causes Mlc1 reduced expression and mislocalization
(Hoegg-Beiler et al., 2014). These results are in agreement with
similar clinical phenotypes among MLC2A and MLC1 patients
(Hamilton et al., 2018).
Animal models have also been very useful in defining the
biochemical relationships between different proteins related to
GlialCAM/MLC1 cell biology. A clear example is a biochemical
and functional interaction between GlialCAM/MLC1 and the
chloride channel ClC-2. Lack of Mlc1 or Glialcam causes
ClC-2 mislocalization (Hoegg-Beiler et al., 2014), which is
completely abolished in Bergmann glia and strongly diminished
at the astrocytic endfeet in the whole brain (Dubey et al.,
2015; Bugiani et al., 2017). Furthermore, in vivo measurements
of ClC-2 activity in cerebellar slices appeared linear in
oligodendrocytes from wild-type mice, and inwardly rectifying
from Glialcam or Mlc1 knockout mice (Hoegg-Beiler et al.,
2014). Other possible functional and biochemical interactions
such as the VRAC channel (containing LRRC8A), Na+/K+-
ATPase, Kir4.1, AQP4 or TRPV4 have not been demonstrated
in vivo, since its localization is preserved in MLC knockout
mice (Hoegg-Beiler et al., 2014; Dubey et al., 2015; Bugiani
et al., 2017). Hence, these proteins might be indirectly
regulated by unknown mechanisms or changes in their activity
could be a consequence of a compensatory mechanism.
Thus, we can conclude that many different processes might
be affected by the lack of GlialCAM and MLC1. How
GlialCAM and MLC1 regulate all these processes needs to
be elucidated to define novel therapeutic strategies. In this
respect, we explored the strategy of gene therapy as an
approach to restore normal MLC1 protein levels in vivo, as
detailed below.
GENE THERAPY FOR MLC
There are several major choices when developing a gene therapy
strategy for a disease like MLC, involving the CNS, which
can influence the efficiency of the treatment. This includes
the type of vector, its route of administration, the diffusion
of the therapeutic protein if can be secreted, or the need for
a cell-specific promoter. Among the available gene delivery
vectors, adeno-associated virus (AAV) vectors have several
features that make them appropriate for brain gene transfer and
one of the most promising for human trials: (i) the capacity
for generating long-term gene expression, as long as 15 years in
non-human primate CNS (Sehara et al., 2017) mostly as episomal
form, thus, avoiding the risk for insertional mutagenesis reported
with integrative vectors; (ii) the absence of toxicity associated
with wild type virus (AAV vectors are classified as Biosafety
Level 1), combined with the absence of wild type viral genes;
and (iii) the ability to easily produce pure high-titer viruses in
the laboratory.
Current technology allows us to efficiently target a localized
brain region, for instance, the substantia nigra in Parkinson’s
disease, in which case direct intraparenchymal injection is
needed. This brings us to another important decision: the
appropriate route of administration has to be approached for
each disease. Direct administration of the vector to a reduced
and specific area of the brain through intracranial injection is
only suitable when the therapeutic protein needs to be localized
in a particular structure, limiting the diffusion of the vector.
Intracranial administration is extremely invasive and there is
an upper limitation of dose and volume to avoid toxicity and
inflammation, although it has the advantage of using lower vector
volumes, thus facilitating vector production.
When the therapeutic protein can be secreted to the
extracellular space, cross-correction from a reduced number of
cells producing the protein can be enough to achieve therapeutic
effects in most cells, independently of the transduced cell
type. This is the case of some lysosomal storage diseases like
mucopolysaccharidoses, where the lysosomal enzyme is partially
secreted and recaptured through the mannose-6-phosphate
receptor. However, in the case of MLC disease, as MLC1 and
GlialCAM proteins are located in the cellular membrane of
astrocytes, we might need to transduce as many astrocytes
as possible.
Indeed, many neurological disorders need a global
distribution of the therapeutic protein to the whole brain
or at least to large CNS structures. Moreover, some brain
areas are more refractory to transduction by global routes of
administration, including the cerebellum, and need a specific
approach (Bosch et al., 2000). For the Mlc1 KO mouse, where
most histological abnormalities are present in the cerebellum,
we explored different delivery routes involving intravenous (IV),
CSF direct administration at lumbar or at the cerebellar area and
directly into the cerebellar parenchyma, into the white mater or
in the molecular layer (Figure 3). Ideally, IV administration of
the vector would be the route of choice if a single injection could
reach the whole brain, without using more interfering surgeries.
However, most vectors are not able to cross the blood-brain
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FIGURE 3 | Representation of the different routes of administration to deliver viruses into the cerebellum. Lumbar intrathecal (IT), Intracerebroventricular (ICV),
Intracerebellar (ICB), white matter (ICB WM), ICB molecular layer (ICB ML), and ICB subarachnoid space (ICB SB).
barrier (BBB). Recently, the capacity of transducing the CNS
through the circulation was shown for AAV9 and some derivates
(like PHP.B; Foust et al., 2009; Deverman et al., 2016). However,
PHP.B efficiency was demonstrated in C57/bl6 mouse strain
(Deverman et al., 2016) but not in Balb/c mice (Hordeaux et al.,
2018), and more importantly, the receptor used by this modified
AAV capsid is not found in non-human primates (Hordeaux
et al., 2019), which relegates the use of this vector to mouse
preclinical studies. Intravenous AAV9 administration, however,
can reach global areas in the cerebrum where it transduces
astrocytes and neurons, as well as in the spinal cord, and is
currently being applied to some clinical trials, particularly
for very young children, in which the BBB is still not well
closed. Encouraging results for spinal muscular atrophy and
Mucopolysaccharidosis type IIIA have been reported so far
(NCT02122952 and NCT04088734 in www.clinicaltrials.gov,
respectively; Mendell et al., 2017). But, to achieve therapeutic
levels of the transgene into the CNS when reaching it from the
circulation, high titers of viruses need to be infused into the
patients (>1014 vg/kg), with the risk of adverse secondary effects,
some of which may be related to liver and dorsal root ganglia
toxicity, as were seen in NHP and piglets (Hinderer et al., 2018).
Moreover, the scale-up of vector production for human clinical
trials is also challenging due to the high virus load needed for
each patient.
Distribution of the vector through the cerebrospinal fluid
(CSF) has many advantages, as allows for a more restricted
expression, compared to the IV; but better global CNS
transduction, compared to intraparenchymal administration;
and it requires lower amounts of viruses, thus increasing
biosafety and lowering production constraints (Pagès et al.,
2019). Moreover, particularly for lumbar puncture, it can be
performed in an outpatient setting, as is much less invasive
than intracranial administration. In the MLC mouse model,
the best results were obtained by delivering the vector into the
CSF by occipital subarachnoid administration, achieving a high
percentage of transduction of the cerebellum without damaging
the brain parenchyma, allowing for a more localized and
efficient action and avoiding non-specific effects due to systemic
expression (Sánchez et al., 2020). By this route, we efficiently
achieved transduction inmost of the cerebellar parenchyma, with
the highest efficacy in the Bergmann glia, where MLC1 is highly
expressed (Figure 4). Given the small volume in the cerebellar
intrathecal cavity, the best diffusion was achieved by loading
the virus at a very slow rate (Huda et al., 2014), which in turn
may decrease the amount of virus drained to the periphery
(Wang et al., 2018).
It is well known that AAV vectors inherently transduce
neuronal cells, so when neurons are not the target cell and to
avoid undesirable secondary effects, it is important to restrict
FIGURE 4 | Biodistribution of AAVrh10 coding for GFP under the regulation
of Glial-derived fibrillary acidic protein recombinant promoter (GFAP).
Cerebellar administration of the adeno-associated virus (AAV) vector in the
subarachnoid space efficiently transduces the whole cerebellum. Scale bar,
400 µm. Reprinted by permission from Springer Nature: Springer,
Neurotherapeutics, Cerebellar Astrocyte transduction as gene therapy for
megalencephalic leukoencephalopathy, Sánchez et al. (2020).
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FIGURE 5 | Gene therapy for MLC corrects cerebellar leukodystrophy and MLC1, GlialCAM, and ClC-2 protein complex. Mlc1 KO mice show myelin vacuolization
in the cerebellum, as a result of lack of MLC1 and mislocalization of GlialCAM and ClC-2. AAV-mediated gene therapy restores MLC1 and allows the formation of the
MLC1-GlialCAM-ClC-2 protein triad, which is enough to correct the vacuolating phenotype of this model.
expression to the target cell type. This is possible by combining
a particular AAV serotype with the control of the transgene
expression by recombinant promoters that recruit specific host
cell-derived transcription factors (Lawlor et al., 2009). To design
a gene therapy strategy for MLC, and taking into account
that MLC1 is exclusively expressed by astrocytes in the brain,
we choose an AAVrh10 vector (Sánchez et al., 2020), as it
seems to transduce a larger number of glial cells in the adult
brain, compared to AAV9 that showed a higher and specific
tropism for neurons (Petrosyan et al., 2014). AAVrh10 was
used in combination with a glial-derived fibrillary acidic
protein recombinant promoter (GFAP), with high selectivity
for astrocytes in the mature mouse brain (Brenner et al.,
1994). Moreover, using a non-human primate serotype such as
AAVrh10, we may increase the possibilities to avoid preexisting
neutralizing antibodies in patients due to previous natural
infections by human parvovirus, present in nature (Thwaite et al.,
2015). Indeed, a high percentage of the human population is
seropositive for AAV2 (Calcedo et al., 2009) and although there
may be some cross-recognition between antibodies raised against
different serotypes, this may decrease using viruses from other
species (Thwaite et al., 2015). This is particularly important in
adult patients, as they have been exposed to various infections
throughout their life.
A dose-escalation study demonstrated a correlation between
MLC1 expression and the degree of correction of the white
matter vacuolation in the cerebellum of treated KO mice
(Sánchez et al., 2020). However, wild-type animals injected with
MLC1 did not show any deleterious effect, contrary to what was
reported in the MLC1 over-expressing transgenic animal (Sugio
et al., 2017), reinforcing the safety of the strategy and indicating
that only supra-physiological levels of MLC1 may be toxic.
Indeed, western blot analysis detected considerably lower levels
of MLC1 in treated KO than in wild type animals, suggesting that
a low amount of protein could still be therapeutic, as expected for
a recessive disease.
We tested two different approaches, first a preventive strategy,
treating the animals before the beginning of the pathology
and analyzing them at 8 months of age, when the cerebellar
vacuolation is evident. In the Mlc1 KO mouse, increased
MLC1 expression in Bergmann glia corrected GlialCAM and
ClC-2 location in this area, confirming that the ternary complex
formed by the three proteins is more stable at the plasma
membrane, as previously seen in vitro and in vivo (Sirisi
et al., 2017). Furthermore, myelin vacuoles were significantly
reduced in number and size (Figure 5). More importantly,
when the animals were treated at the beginning of the
symptomatology, we not only prevented the onset of the
cerebellar abnormalities but also significantly reduced the
vacuolating phenotype in the transduced tissues. In fact, no
differences were seen between the preventive and the therapeutic
group at 8 months of age.
Based on the remitting edema phenotype of MLC2B patients,
who carry one dominant mutation in the HEPACAM gene, we
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hypothesized that in vacuolating leukoencephalopathies such as
MLC, or as it was demonstrated for similar pathologies such as
Canavan’s or Pelizaeus-Merzbacher-like disease (Georgiou et al.,
2017; Gessler et al., 2017), the therapeutic correction could be
achieved even in advanced stages of the disease. Importantly, in
this type of disease, there is no marked neuronal degeneration,
and possibly the clinical phenotype could be reversible. Indeed,
the results obtained from animals treated at 15 months of age,
almost 1 year after the development of the vacuolating pathology,
demonstrated a similar level of correction to animals treated as
asymptomatic (Sánchez et al., 2020). This is relevant for therapy,
as indicates that we may have a wide therapeutic window for
these patients and they might be treated at any age, while in most
neurodegenerative diseases, successful treatment is conditioned
to very early intervention, thus, subjected to their perinatal
detection, only if they have older affected siblings, or through
perinatal screening, which unfortunately is still not the case for
many inherited diseases.
This study is only a proof of concept of the feasibility of
gene therapy for MLC. Therefore, the translatability of this
approach needs to be further confirmed as human patients
display pathology through the whole brain. However, some
of the most severe symptoms such as mobility problems
might be partially related to cerebellar pathology, so, it
needs to be tested whether expression of MLC only in
the cerebellum is enough to ameliorate these symptoms.
Nevertheless, other phenotypes such as autism or cognitive
deterioration might be more difficult to correct since
these phenotypes may be the consequence of alteration of
developmental processes at very early stages. Whether the
mouse model may reveal higher susceptibility to develop
epileptic seizures after kainate insults (Dubey et al., 2018)
and if this may be corrected after gene therapy, remains to
be evaluated. Anyway, extrapolating from the tiny mouse
cerebellum to the same structure in young children is
challenging. So, probably we will need to deliver the virus
through multiple injections, although other strategies like
convection-enhanced administration should be assayed in
larger animals such as non-human primates, dogs, or pigs
(Lonser et al., 2015).
There are still several important concerns to be studied
in this disease before thinking in a human clinical trial. It
would be interesting to see if gene therapy in the Glialcam
KO mouse model can mimic the results obtained in the
Mlc1 KO mouse. Whether GlialCAM needs to be expressed
in both oligodendrocytes and astrocytes to recover normal
histology, or which of these cell types has a major role in
the development of the disease are questions that need to be
answered. Administration of AAVs coding for GlialCAM under
the regulation of an astrocyte or an oligodendrocyte-specific
promoter may give us the clue for this question. Other AAV
serotypes or capsid modifications to increase vector tropism
for glial cells (Powell et al., 2016), using tandem promoters for
both cell types (Colella et al., 2019) or detargeting the neuronal
tropism of AAVs by using microRNAs may also increase the
efficiency of the strategy (Colin et al., 2009).
Importantly, to follow the progression of the disease in
gene therapy clinical trials we need to select appropriate
readouts. Alternatively, the development of larger animal models
deficient for GlialCAM or MLC1 may facilitate direct invasive
procedures and to follow physiological in vivo approaches such
as structural and functional imaging of small brain structures,
which is not possible in a mouse brain, and may open the
possibility to develop new in vivo imaging biomarkers. Moreover,
larger animal models may facilitate CSF collection, and will
allow finding richer behavioral phenotypes which will make
more complex behavioral testing possible. Besides, it will allow
assessing for a larger biodistribution of the vector in the brain and
possibly identifying new parameters to follow in patients during
gene therapy treatment.
CONCLUSIONS AND PERSPECTIVES
The first gene for MLC (MLC1) was identified 20 years
ago. Although many discoveries have been made in this
long journey, the exact function of the MLC1 protein is not
known and there are no therapeutic interventions for MLC
patients. We expect that novel results will provide wider
perspectives of the pathophysiology of the disease, which
will help to clarify MLC protein’s role in glial cell biology.
Hopefully, this knowledge will be accompanied by advanced
therapeutic solutions.
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